Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid-containing glycoconjugates, commonly referred to as sialoglycans, are complex sugar chains terminating in sialic acid residues that densely coat the surface of human cells, forming a major component of the cellular glycocalyx. These molecules play critical roles in physiological processes, including cell-cell recognition, cell adhesion, and immune system regulation. In healthy states, sialoglycans act as 'self' markers, interacting with sialic acid-binding immunoglobulin-like lectins (Siglecs) on immune cells to suppress inappropriate immune activation. However, in many cancers, tumor cells undergo hypersialylation, upregulating sialoglycans to exploit this pathway as a glyco-immune checkpoint, thereby evading both innate and adaptive immune surveillance.\n\nTherapeutic strategies targeting these cell surface sialoglycans focus on disrupting this immunosuppressive axis. Novel biotherapeutics, such as Palleon Pharmaceuticals' engineered human sialidase-Fc fusion proteins (e.g., E-602) and tumor-targeted sialidases (e.g., E-688/HLX316), enzymatically strip terminal sialic acids from the tumor and immune cell surfaces. This desialylation unmasks the tumor cells, preventing their interaction with inhibitory Siglec receptors and restoring robust anti-tumor immune responses. Additionally, specific monoclonal antibodies (such as FG129) are being developed to target tumor-associated sialoglycans for direct cell killing or payload delivery.
Enzymatic desialylation of cell surface glycans to disrupt sialoglycan-Siglec interactions and restore immune cell activation; targeted antibody binding to tumor-associated sialoglycans to induce cell death
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid-containing glycoconjugates on human cell surfaces.